Kiniksa Pharmaceuticals International, plc (formerly Kiniksa Pharmaceuticals, Ltd.)

Kiniksa is a London-domiciled, US-operated commercial-stage biopharmaceutical company whose economics today rest almost entirely on ARCALYST (rilonacept), a weekly subcutaneous IL-1α/IL-1β cytokine trap licensed from Regeneron and the first and only FDA-approved therapy for recurrent pericarditis (approved March 2021). The company has converted a niche orphan cardiology indication into a franchise generating $677.6M of net product revenue in FY2025 (+62% YoY) and guided to $980–995M for FY2026, with net income turning sustainably positive in 2025 ($59.0M). Kiniksa shares ARCALYST profits 50/50 with Regeneron, which also manufactures the drug. Having discontinued autoimmune programmes (abiprubart, vixarelimab, mavrilimumab) to concentrate on cardiovascular inflammation, it is now developing next-generation IL-1 receptor antibodies — KPL-387 (monthly dosing, Phase 3 PASTORALE trial underway) and KPL-1161 (quarterly dosing, preclinical) — designed to extend its leadership in recurrent pericarditis beyond ARCALYST's exclusivity horizon.

---

Company's own description

In every 2025–2026 press release, Kiniksa describes itself as a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications. In earlier periods (2018–2023) it framed itself more broadly around immune-modulating assets across a spectrum of diseases; the pivot to a cardiovascular focus was formalized in February 2025 when the company discontinued abiprubart in Sjögren's Disease and announced KPL-387 development in recurrent pericarditis (8-K, 25 February 2025).

Independent characterization

Kiniksa is best understood as a single-asset commercial orphan cardiology company with a self-funded follow-on pipeline. Its business model has four distinctive features:

1. In-licensed commercial asset, profit-share economics. ARCALYST was originally approved (2008) and marketed by Regeneron for cryopyrin-associated periodic syndromes (CAPS). Kiniksa licensed it in September 2017, ran the pivotal RHAPSODY trial in recurrent pericarditis, won FDA approval in March 2021, and took over US commercialization of all ARCALYST indications. Under the Regeneron agreement Kiniksa books 100% of net product revenue but records "collaboration expenses" equal to Regeneron's share of collaboration profit (effectively ~50% of profit after defined costs). In FY2025 collaboration expenses were $229.5M against $677.6M of revenue (FY2025 press release).

2. Outsourced manufacturing. Regeneron supplies ARCALYST drug product; Kiniksa carries manufacturing purchase commitments ($232.5M non-cancellable at 31 Dec 2024, of which $94.9M due within one year, per FY2024 10-K).

3. Specialty-pharmacy, high-touch commercial model. ARCALYST is distributed through specialty channels with a hub/patient support program (Kiniksa OneConnect). Targeting is concentrated on cardiologists and pericardial disease centres; the company reports >5,000 launch-to-date prescribers and ~29% of prescribers having treated two or more patients (Q2 2026 call).

4. Out-licensing to monetize non-core assets. License and collaboration revenue (Genentech for vixarelimab; Huadong Medicine for mavrilimumab and rilonacept in Asia-Pacific) contributed $97.7M (FY2022), $37.1M (FY2023), $6.2M (FY2024) and nil in FY2025.

Revenue model mix

Source: Form 10-K FY2022, FY2023, FY2025; FY2023 and FY2025 earnings releases.

There is no service or subscription revenue. The company is now a pure product-revenue business.

Value-chain position, customers and end markets

Value-chain position: Late-stage developer and commercializer (clinical development, regulatory, market access, sales/marketing). Discovery is limited; manufacturing is outsourced (Regeneron for ARCALYST; CDMOs for pipeline — specific CDMOs n/d).

Direct customers: Specialty pharmacies and specialty distributors (individual customer concentration percentages n/d in sources reviewed).

Prescribers: Cardiologists (general and pericardial specialists), rheumatologists, and other HCPs; the company estimates >25,000 HCPs see recurrent pericarditis patients annually (Q1 2026 call).

Payers: US commercial insurers, Medicare Part D (materially affected by the Inflation Reduction Act's 2025 Part D redesign), and Medicaid.

End markets: (i) Recurrent pericarditis (primary; ~14,000 US patients with multiple recurrences cited as the core target population); (ii) CAPS and deficiency of IL-1 receptor antagonist (DIRA) — legacy rare autoinflammatory indications (revenue split by indication n/d); (iii) Asia-Pacific (ex-Japan) via Huadong partnership.

Stated strategic themes

1. Extend leadership in recurrent pericarditis — drive ARCALYST penetration beyond ~21% of the multiple-recurrence population through new and repeat prescriber growth; the company describes its position as "established leadership in recurrent pericarditis market."

2. Lifecycle management through next-generation IL-1 blockade — KPL-387 (monthly, liquid) and KPL-1161 (quarterly) to offer more convenient dosing and extend franchise duration beyond ARCALYST's orphan exclusivity.

3. Cardiovascular focus — explicit prioritization of cardiovascular indications, formalized by discontinuing abiprubart (Feb 2025).

4. Self-funded growth and financial discipline — "operating plan expected to remain cash flow positive on an annual basis."

5. Disciplined business development — management remains open to BD but applies "a high bar" and prioritizes internal value creation (Q1 2026 call).

Strategic initiatives in the last 24 months

Management guidance and medium-term targets

Kiniksa has met or beaten its initial annual ARCALYST guidance every year since launch, typically raising guidance two or more times within the year. No long-range (e.g., 2028–2030) revenue or margin targets have been published.

Kiniksa has one marketed product and two active clinical/preclinical programmes, plus several discontinued or out-licensed assets.

Marketed product

ARCALYST® (rilonacept)

Description: Dimeric fusion protein ("cytokine trap") comprising the ligand-binding domains of IL-1 receptor (IL-1R1) and IL-1 receptor accessory protein linked to human IgG1 Fc; binds and neutralizes IL-1α and IL-1β.

Administration: Weekly subcutaneous injection, supplied as lyophilized powder requiring reconstitution.

Approved indications (US): (1) Recurrent pericarditis and reduction in risk of recurrence in adults and pediatric patients ≥12 years (approved 18 March 2021); (2) CAPS, including familial cold autoinflammatory syndrome and Muckle-Wells syndrome, in adults and children ≥12 (originally approved 2008 for Regeneron); (3) Maintenance of remission of DIRA in adults and pediatric patients weighing ≥10 kg (approved December 2020).

Regulatory protection: US Orphan Drug Exclusivity for recurrent pericarditis granted March 2021 (seven years, i.e., to approximately March 2028). European Commission Orphan Drug designation in idiopathic pericarditis (July 2026 corporate presentation). Biologic reference-product exclusivity for the original 2008 BLA has lapsed; composition patent status n/d in sources reviewed.

Commercial metrics (Q2 2026 release and call): ~21% penetration of the ~14,000 multiple-recurrence US patient population; >5,000 launch-to-date prescribers (~450 new prescribers in Q2 2026); >50% of new prescriptions from repeat prescribers; average total duration of therapy ~3 years; year-to-date 2026 gross-to-net 7.2% (FY2025: 8.4%; FY2024: 9.8%).

Pricing: WAC per vial/annual cost n/d in sources reviewed. Gross-to-net discounts reported as above.

Patient services: Kiniksa OneConnect (trademarked patient support/hub programme).

Territories: Kiniksa holds rights outside the Middle East/North Africa (retained by Regeneron per presentation footnote); Huadong Medicine holds exclusive rights in Asia-Pacific excluding Japan.

Sources: Quarterly 8-K earnings releases. Q1 2025 benefited from a one-time patient bolus linked to the IRA Medicare Part D redesign (Q4 2025 earnings commentary).

Clinical and preclinical pipeline

KPL-387 (monoclonal antibody IL-1 receptor antagonist)

Mechanism: Fully human IgG2 monoclonal antibody binding IL-1R1, blocking signaling of both IL-1α and IL-1β.

Target product profile: Single once-monthly subcutaneous injection in a liquid formulation (vs. ARCALYST's weekly lyophilized injection).

Status: Phase 2/3 trial in recurrent pericarditis (NCT07010159; ~165 participants planned across ~52 sites). Phase 2 interval analysis (28 July 2026): 300 mg SC monthly produced rapid and sustained reductions in pain and inflammation, efficacy durable across the monthly dosing interval, and was generally well tolerated; 300 mg selected for Phase 3. Pivotal Phase 3 portion, PASTORALE, is enrolling up to ~85 participants with a randomized-withdrawal style primary endpoint of reduction in risk of recurrence (mirroring RHAPSODY). A supplemental Phase 2 "Transition to KPL-387 Monotherapy" study is evaluating dosing regimens to switch patients from standard therapies.

Regulatory: FDA Orphan Drug Designation for pericarditis (2025).

Timeline: Development programme designed to enable a 2028/2029 launch (July 2026 Q2 presentation).

KPL-1161 (Fc-modified IL-1 receptor antagonist antibody)

Mechanism: Independently developed, Fc-modified IgG2 monoclonal antibody binding IL-1R1, inhibiting IL-1α and IL-1β.

Target product profile: Quarterly subcutaneous dosing.

Status: IND-enabling/preclinical; Phase 1 first-in-human trial expected to initiate by end of 2026.

Discontinued, deprioritized and out-licensed assets